報價延遲最少15分鐘:2026/04/21 20:01 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
9.22 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-24.70/--
|
|
企業價值
88.45M
|
| 資產負債 |
|
每股賬面淨值
2.96
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a singleoperating segment, developing and commercializing therapeutics. |
